| Name | 3-(3-Aminophenyl)-4-(1-methyl-1H-indol-3-yl)pyrrole-2,5-dione |
|---|---|
| Synonyms |
3-(3-Aminophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
1H-Pyrrole-2,5-dione, 3-(3-aminophenyl)-4-(1-methyl-1H-indol-3-yl)- CP21R7 CP21 CP-21R7 |
| Description | CP21R7 is potent GSK-3β inhibitor, with an IC50 of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC50 of 1900 nM. |
|---|---|
| Related Catalog | |
| Target |
GSK-3β:1.8 nM (IC50) PKCα:1900 nM (IC50) |
| In Vitro | CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC50 of 1.8 nM; the IC50 of CP21R7 against PKCα is 1900 nM[1]. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm[2]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 627.4±55.0 °C at 760 mmHg |
| Molecular Formula | C19H15N3O2 |
| Molecular Weight | 317.341 |
| Flash Point | 333.2±31.5 °C |
| Exact Mass | 317.116425 |
| LogP | 2.40 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.714 |
| Storage condition | -20℃ |